![](https://news.europawire.eu/wp-content/uploads/2013/12/Professor-Klaus-Dugi-132x150.jpg)
For media outside of the US, the UK & Canada only The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics1,2,3,4 Pooled safety data favour Pradaxa® treatment over warfarin and provide further reassurance1-4 The analysed … Read the full press release